INT203099

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.82
Pain Relevance 1.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Aes (Mus musculus)
Pain Link Frequency Relevance Heat
Infliximab 108 99.56 Very High Very High Very High
methotrexate 96 98.20 Very High Very High Very High
Etanercept 108 91.92 High High
withdrawal 21 84.04 Quite High
Paracetamol 1 81.60 Quite High
tolerance 4 77.68 Quite High
agonist 33 64.32 Quite High
rheumatoid arthritis 21 50.00 Quite Low
Leflunomide 4 49.04 Quite Low
Arthritis 6 15.40 Low Low
Disease Link Frequency Relevance Heat
Vomiting 10 100.00 Very High Very High Very High
Diabetes Mellitus 109 92.00 High High
Obesity 8 77.68 Quite High
Weight Loss 14 77.32 Quite High
Overweight 7 69.88 Quite High
Body Weight 12 50.64 Quite High
Rheumatoid Arthritis 23 50.00 Quite Low
Aging 2 24.96 Low Low
Disease 37 5.00 Very Low Very Low Very Low
Hypoglycemia 30 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
One mechanism underlying this difference could be the formation of neutralising and immunopathogenic antibodies against the murine part of infliximab, leading to a higher number of AEs [16].
Negative_regulation (number) of AEs associated with infliximab
1) Confidence 0.25 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1794519 Disease Relevance 0 Pain Relevance 0.59
It can also be speculated that MTX in turn can effectively inhibit the formation of these immunopathogenic antibodies, thus decreasing the risk for AEs [16-18].
Negative_regulation (decreasing) of AEs associated with methotrexate
2) Confidence 0.25 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1794519 Disease Relevance 0 Pain Relevance 0.55
1 OHA, this dose of exenatide LAR resulted in comparable reductions in HbA1c, fasting glucose and weight after 30 weeks of treatment, with a reduced incidence and severity of nausea and other GI AEs than, exenatide 10 ?
Negative_regulation (reduced) of AEs associated with vomiting
3) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.82 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox